| 20.27 0.82 (4.22%) | 12-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 26.25 |
1-year : | 29.52 |
| Resists | First : | 22.47 |
Second : | 25.28 |
| Pivot price | 21.27 |
|||
| Supports | First : | 17.95 |
Second : | 14.93 |
| MAs | MA(5) : | 21.01 |
MA(20) : | 20.76 |
| MA(100) : | 21.19 |
MA(250) : | 27.73 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 26.6 |
D(3) : | 39.3 |
| RSI | RSI(14): 48.2 |
|||
| 52-week | High : | 41.02 | Low : | 16.53 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ FTRE ] has closed above bottom band by 30.1%. Bollinger Bands are 4.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 20.55 - 20.66 | 20.66 - 20.77 |
| Low: | 18.71 - 18.85 | 18.85 - 18.99 |
| Close: | 20.05 - 20.27 | 20.27 - 20.47 |
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. It operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is based in Durham, North Carolina.
Thu, 12 Dec 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRE - The Eastern Progress Online
Mon, 09 Dec 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRE - PR Newswire
Mon, 09 Dec 2024
Charles Schwab Investment Management Inc. Acquires 29,285 Shares of Fortrea Holdings Inc. (NASDAQ:FTRE) - MarketBeat
Sun, 08 Dec 2024
Holocene Advisors LP Sells 115,412 Shares of Fortrea Holdings Inc. (NASDAQ:FTRE) - MarketBeat
Sat, 07 Dec 2024
Fortrea (NASDAQ:FTRE) Shares Gap Down - Here's What Happened - MarketBeat
Sat, 07 Dec 2024
Investors Purchase Large Volume of Fortrea Call Options (NASDAQ:FTRE) - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 90 (M) |
| Shares Float | 75 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 113 (%) |
| Shares Short | 5,510 (K) |
| Shares Short P.Month | 7,290 (K) |
| EPS | -2.45 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 16.87 |
| Profit Margin | -10.1 % |
| Operating Margin | -1.4 % |
| Return on Assets (ttm) | -1.1 % |
| Return on Equity (ttm) | -13.6 % |
| Qtrly Rev. Growth | -5.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 33.22 |
| EBITDA (p.s.) | 0.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 263 (M) |
| Levered Free Cash Flow | 368 (M) |
| PE Ratio | -8.31 |
| PEG Ratio | 0 |
| Price to Book value | 1.2 |
| Price to Sales | 0.61 |
| Price to Cash Flow | 6.91 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|